Cargando…

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach

To better understand heart failure with preserved ejection fraction (HFpEF), we need to better characterize the transition from asymptomatic pre-HFpEF to symptomatic HFpEF. The current emphasis on left ventricular diastolic dysfunction must be redirected to microvascular inflammation and endothelial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayes-Genis, Antoni, Bisbal, Felipe, Núñez, Julio, Santas, Enrique, Lupón, Josep, Rossignol, Patrick, Paulus, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230997/ https://www.ncbi.nlm.nih.gov/pubmed/32294958 http://dx.doi.org/10.3390/jcm9041110

Ejemplares similares

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum
por: Santas, Enrique, et al.
Publicado: (2021)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction
por: Domínguez, Eloy, et al.
Publicado: (2018)

Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)
por: Farré, Nuria, et al.
Publicado: (2017)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis
por: Zamora, Elisabet, et al.
Publicado: (2022)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Coronary microvascular dysfunction and heart failure with preserved ejection fraction: what are the mechanistic links?
por: Sinha, Aish, et al.
Publicado: (2023)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Understanding heart failure with preserved ejection fraction: where are we today?
por: van Heerebeek, L., et al.
Publicado: (2016)

Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience
por: Gastelurrutia, Paloma, et al.
Publicado: (2021)

The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction
por: Weerts, Jerremy, et al.
Publicado: (2021)

A Preclinical Rat Model of Heart Failure With Preserved Ejection Fraction With Multiple Comorbidities
por: Hubesch, Géraldine, et al.
Publicado: (2022)

Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models
por: van Ham, Willem B., et al.
Publicado: (2022)

Development of heart failure with preserved ejection fraction is independent of eosinophils in a preclinical model
por: Pan, Qi, et al.
Publicado: (2023)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure
por: Civera, Jose, et al.
Publicado: (2022)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study
por: Cediel, Germán, et al.
Publicado: (2017)

Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score
por: Huttin, Olivier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cvspnp0erheit7jnstm4sk7mec